News | January 15, 2013

Advanced Radiation Therapy Acquires AccuBoost Assets From Elekta

radiation therapy

January 14, 2013 — Advanced Radiation Therapy (ART), manufacturer of the AccuBoost System for radiation therapy of partial breast and Elekta a global leader in cancer management systems and software, announced today that they have executed an agreement whereby ART acquires the assets of all AccuBoost installations held by Elekta, its worldwide distribution partner. As part of the transaction, ART has purchased the assets and the operating agreements for more than 20 installations in the U.S. The transaction is designed to enable both companies to focus on their core competencies, and serves AccuBoost user groups by allowing ART to increase its support to these installations.

Piran Sioshansi, Ph.D., President and CEO of ART, stated: "The support of Nucletron/Elekta has been helpful for the growth of the AccuBoost product to become an established treatment option for partial breast radiation therapy in the United States. With this agreement, AccuBoost will resume its lead position in support of the treatment centers and concentrate on future growth of the technology and accelerate the introduction of new treatment options."

"AccuBoost is well positioned to enter into a stage of substantial growth," Dr. Sioshansi continued, "and plans to hire additional staff and work independently with all of the providers in the radiation oncology marketplace."

Bill Dowd, Vice President, Brachytherapy, North America with Nucletron, an Elekta Company, stated: "We believe this is the best way forward for the development of AccuBoost and for customers using this solution."

The AccuBoost procedure is designed for women diagnosed with early stage breast cancer who pursue Breast Conserving Therapy (BCT). AccuBoost is a new brachytherapy modality that uses real time image guidance to target the radiation dose for patients who choose BCT. The mammography image-guided AccuBoost partial breast irradiation procedure is offered either for breast boost therapy, as part of the course of whole breast irradiation regimen or as a non-invasive monotherapy option for Accelerated Partial Breast Irradiation (APBI).

For more information: www.artcorporation.net

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Women Prefer Getting Mammograms Every Year
News | Mammography | January 09, 2018
Women prefer to get their mammograms every year, instead of every two years, according to a new study presented at the...
Planmed Clarity 2-D Digital Mammography System Receives FDA Approval
Technology | Mammography | January 08, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the Planmed Clarity 2-D full-field digital...
Overweight Women May Need More Frequent Mammograms
News | Mammography | January 04, 2018
Women with higher body mass index (BMI) face an increased risk of not detecting their breast tumor until it has become...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Overlay Init